Sato Yuta, Jingu Keiichi, Umezawa Rei, Yamamoto Takaya, Ishikawa Yojiro, Takeda Kazuya, Suzuki Yu, Matsushita Haruo
Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-chou, Aoba-ku, Sendai, 980-8574 Japan.
Int Cancer Conf J. 2020 Jul 3;9(4):227-230. doi: 10.1007/s13691-020-00431-5. eCollection 2020 Oct.
A 56-year-old male with stage IIIA (UICC 7th) non-small cell lung cancer (adenocarcinoma) received radiotherapy with 66 Gy/33 fractions concomitant with CBDCA and PTX. A partial response was achieved after chemoradiotherapy and the tumor continued to shrink over a period of 1 year; however, regrowth of the tumor attached to the aortic arch was observed without any other residual tumor or metastases. We diagnosed recurrence with slightly increased F-FDG uptake (maximum standardized uptake value: 12.2). Stereotactic radiotherapy was performed for the relapsed lesion with 60 Gy/10 fractions. The patient has survived for more than 5 years after stereotactic radiotherapy without recurrence or metastases, although he has been suffering from chest pain that has required treatment with a low dose of oxycodone.
一名56岁男性，患有IIIA期（国际抗癌联盟第7版）非小细胞肺癌（腺癌），接受了66 Gy/33次分割的放疗，同时使用卡铂（CBDCA）和紫杉醇（PTX）。放化疗后取得部分缓解，肿瘤在1年时间内持续缩小；然而，观察到附着于主动脉弓的肿瘤复发，无任何其他残留肿瘤或转移灶。我们诊断为复发，氟代脱氧葡萄糖（F-FDG）摄取略有增加（最大标准化摄取值：12.2）。对复发灶进行了60 Gy/10次分割的立体定向放疗。立体定向放疗后，患者已存活超过5年，无复发或转移，尽管他一直遭受胸痛，需要用低剂量羟考酮治疗。
